The author additionally defined 28/118 (24%) cases as HER2-low; these results could be of potentially therapeutic value, given the recent discovery in breast cancer (BC) setting that patients with HER2-low cancer could also benefit from anti-HER2 therapy. Here, ERBB2 is linked to cancer.